AI Article Synopsis
- Activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) has poorer survival outcomes using the standard RCHOP treatment compared to the germinal center B-cell-like (GCB) subtype.
- Preliminary evidence indicates that new treatments may work better for certain subtypes of DLBCL, leading researchers to explore cost-effective treatment strategies based on these subtypes.
- A micro-simulation model suggested that a subtype-based treatment approach, using lenalidomide plus RCHOP for ABC DLBCL, resulted in favorable cost-effectiveness, but further phase 3 trial data is necessary for confirmation.
Article Abstract
Activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) is associated with worse survival after standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) chemoimmunotherapy compared to germinal center B-cell-like (GCB) subtype. Preliminary evidence suggests that benefits from novel agents may vary by subtype. Hypothesizing that treatment stratified by DLBCL subtype could be potentially cost-effective, we developed micro-simulation models to compare three first-line treatment strategies: (1) standard RCHOP for all patients (2) subtype testing followed by RCHOP for GCB and novel treatment for ABC DLBCL, and (3) novel treatment for all patients. Based on phase 2 evidence, we used lenalidomide + RCHOP as a surrogate novel treatment. The subtype-based approach showed a favorable incremental cost-effectiveness ratio of $15,015/quality-adjusted life year compared with RCHOP. Although our exploratory analyses demonstrated a wide range of conditions where subtype-based treatment remained cost-effective, data from phase 3 trials are needed to validate our models' findings and draw definitive conclusions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918224 | PMC |
| http://dx.doi.org/10.1080/10428194.2017.1390230 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting phage-host interactions via feature augmentation and regional graph convolution.
Brief Bioinform
November 2024
Hubei Provincial Key Laboratory of Artificial Intelligence and Smart Learning, Central China Normal University, Wuhan 430079, China.
Identifying phage-host interactions (PHIs) is a crucial step in developing phage therapy, which is the promising solution to addressing the issue of antibiotic resistance in superbugs. However, the lifestyle of phages, which strongly depends on their host for life activities, limits their cultivability, making the study of predicting PHIs time-consuming and labor-intensive for traditional wet lab experiments. Although many deep learning (DL) approaches have been applied to PHIs prediction, most DL methods are predominantly based on sequence information, failing to comprehensively model the intricate relationships within PHIs.
View Article and Find Full Text PDFEpidermal Growth Factor Receptors Unveiled: A Comprehensive Survey on Mutations, Clinical Insights of Global Inhibitors, and Emergence of Heterocyclic Derivatives as EGFR Inhibitors.
J Drug Target
January 2025
Department of Pharmacology, Orotta College of Medicine and Health Sciences, Asmara University, Asmara, P.O. Box: 10549, Eritrea; (I.P).
Mutations that overexpress the epidermal growth factor receptor (EGFR) are linked to cancers like breast (15-20%), head and neck (10-15%), colorectal (5-8%), and non-small cell lung cancer (10-50%), especially in East Asian populations. EGFR activation stimulates "RAS/RAF/MEK/ERK, PI3K/Akt, and MAPK" pathways, which enhance cell division, survival, angiogenesis, and tumor growth while inhibiting apoptosis and metastasis. Secondary mutations (e.
View Article and Find Full Text PDFAdvances in the treatment of high burden Follicular lymphoma: a Comprehensive review.
Leuk Lymphoma
January 2025
Memorial Sloan Kettering Cancer Center, New York, New York, United States.
Follicular lymphoma (FL) represents the second most frequent type of non-Hodgkin lymphoma and the most common indolent histology. The disease course of FL is heterogeneous, likely resulting from diverse molecular and immunological features that drive a broad spectrum of clinical presentations. While some patients with low-volume and asymptomatic disease are suitable for observation, patients with high tumor burden, advanced-stage, or symptomatic disease more often necessitate treatment initiation.
View Article and Find Full Text PDFA high-performance g-CN/BiSiO heterojunction photocatalyst induced by constructing S-scheme electron-highways.
Sci Rep
January 2025
College of Chemistry and Chemical Engineering, Tarim University, Alar, 843300, Xinjiang, China.
We have developed a novel S-scheme mechanism to expand the photoresponse range of BiSiO. This study reports the successful creation of a CN/BS heterojunction photocatalyst, which is composed of g-CN and BiSiO. The synthesis was achieved through a simple two-step procedure, involving hydrothermal treatment and subsequent calcination.
View Article and Find Full Text PDFCircular RNAs in cancer: roles, mechanisms, and therapeutic potential across colorectal, gastric, liver, and lung carcinomas.
Discov Oncol
January 2025
Department of Bioscience and Biotechnology, Banasthali Vidyapith, Niwai-Tonk, Rajasthan, 304022, India.
The prominence of circular RNAs (circRNAs) has surged in cancer research due to their distinctive properties and impact on cancer development. This review delves into the role of circRNAs in four key cancer types: colorectal cancer (CRC), gastric cancer (GC), liver cancer (HCC), and lung cancer (LUAD). The focus lies on their potential as cancer biomarkers and drug targets.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!